My area of expertise lies at the interface of emerging infectious diseases, antibody engineering, and vaccine development. My research is driven by a translational vision to bridge fundamental immunological discoveries with the development of effective medical countermeasures against high-consequence viral pathogens.

My work is anchored by three interconnected pillars:

• Broad-spectrum Antiviral Antibody Discovery & Engineering: A central focus of my career is the discovery and preclinical development of potent, broadly neutralizing antibodies. My representative first-author work in Vita (2026) describes a novel interdomain epitope-targeting antibody that confers protection against Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) in both murine and non-human primate models. I have extensive experience in antibody generation platforms—including hybridoma technology, single-cell V(D)J sequencing, and humanized animal models—as well as in Fc-engineering strategies, such as PEGylation, to optimize pharmacokinetics and therapeutic half-life (International Journal of Molecular Sciences, 2023).

• Novel Vaccine Design & Preclinical Validation: I have deep expertise in designing and evaluating next-generation vaccine platforms, including viral-vectored and strain-based inactivated vaccines. My work encompasses the development of a novel triple inactivated vaccine conferring rapid immunity against feline multisystemic pathogens (Transboundary and Emerging Diseases, 2025), and the construction of a rabies virus-vectored vaccine expressing Marburg virus glycoprotein that elicited neutralizing antibodies in humanized mice (Emerging Microbes & Infections, 2022).

• Host-Pathogen Interaction & Systems Immunology: To inform rational vaccine and therapeutic design, I employ systems-level approaches to dissect host immune responses. This is exemplified by my recent work utilizing single-cell transcriptomics to reveal dysregulated B cell and neutrophil signatures driving inflammatory responses during SFTSV infection (Journal of Medical Virology, 2025).

My research is underpinned by proficient application of diverse methodologies, including high-throughput pseudovirus neutralization assays, reverse genetics, multiplexed immunoassays, and advanced flow cytometry. My standing as a Specially Invited Expert and peer reviewer for journals such as Emerging Microbes & Infections, Advanced Science, and Clinical Microbiology Reviewsreflects my subject matter authority in virology and immunology. As an Associate Research Fellow at Westlake University, my current research program continues to interrogate the molecular determinants of viral immunity to guide the development of countermeasures for pandemic preparedness.